Thyroid eye disease and steroids: what disease activity control actually means

The sentence I hear most often about steroids in thyroid eye disease is that they did not work. When I ask what was expected, the answer is nearly always the same: that the eyes would go back to how they used to look. That is not what the drug is for, and nobody had said so.

Steroids here are aimed at inflammation, which is the process currently changing your orbit. Appearance is the result of changes that have already happened. Two different targets, and the whole logic of treatment rests on telling them apart.

Why am I being offered steroids when it is my eyes that have changed?

Because treatment in thyroid eye disease is chosen on two separate measurements, and only one of them is about how the eye looks. The first is activity, meaning how much inflammation is running right now. The second is severity, meaning how much damage and disruption is present. Steroids answer the first question.

This distinction matters more than any other single idea in the condition. A patient can have very obvious eyes and almost no activity, and another can have unremarkable eyes and a great deal of it. It also explains the shape of the whole plan. Anti-inflammatory treatment has something to work on only while the disease is active, and the operations that change appearance are deliberately held back until it is not. Activity is a phase, not a permanent state. If you are still working out whether what you have is thyroid eye disease, start with the signs and treatment of thyroid eye disease.

What is the Clinical Activity Score and what does my number mean?

It is a seven-item checklist of inflammatory signs, and a score of three or more out of seven means your disease is active. Below three, it is inactive. It is crude and it is binary, and it remains the most thoroughly validated way of answering the one question steroids can act on.

The seven items are spontaneous pain behind the eye, pain on trying to look up or down, redness of the eyelids, redness of the conjunctiva, swelling of the caruncle or plica at the inner corner, swelling of the eyelids, and swelling of the conjunctiva, which is called chemosis. Read that list again and notice what is missing from it.

Nothing on that list measures protrusion, lid height or how you photograph. That is the mechanism behind the sentence I repeat in clinic all day: steroids treat activity, not appearance. Severity is graded on its own, separately, and treatment is chosen on the two measurements together, which is why two people with the same score can reasonably be offered different things.

Will steroids make my eyes stop bulging?

No, and this is where expectation and treatment part company. Steroids can settle redness, swelling, ache and chemosis. They are not a way of pushing an eye back into its socket or of lowering a retracted lid, and no honest consent conversation should imply otherwise.

Severity is graded separately from activity. Mild disease means features with only a minor impact on daily life, usually including lid retraction under two millimetres, mild soft tissue involvement, protrusion under three millimetres above normal for race and sex, and no more than intermittent double vision, with corneal exposure that still responds to lubricants. Moderate to severe disease usually has two or more of the following: lid retraction of two millimetres or more, moderate or severe soft tissue involvement, protrusion of three millimetres or more above normal, and double vision that is inconstant or constant. Sight-threatening means optic nerve involvement or corneal breakdown.

The surgery that changes appearance, meaning orbital decompression, squint surgery and eyelid surgery, is called rehabilitative surgery and is indicated for inactive residual disease. The operations come after the fire is out. Double vision has a mechanical explanation that steroids only partly touch, covered in double vision that is not a squint, and the wider map of the socket sits in orbital conditions explained.

Why a drip rather than tablets, and how much?

Because in moderate to severe and active disease the intravenous route is more effective and better tolerated than oral steroids. Tablets are not a gentler version of the same thing. They are a less effective version carrying more of a burden.

The guideline recommends intravenous methylprednisolone combined with oral mycophenolate as first-line treatment for moderate to severe and active disease. The usual regimen is a cumulative dose of 4.5 grams given as twelve weekly infusions: half a gram once a week for six weeks, then a quarter of a gram once a week for six weeks. Higher cumulative doses, up to 7.5 grams per cycle, may be used as monotherapy in the most severe cases and where double vision is constant or inconstant.

Notice that the guideline writes a ceiling as well as a schedule. The cumulative dose of intravenous glucocorticoids should not exceed eight grams. A drug that arrives with a written limit is telling you something about itself before anyone has mentioned side effects, and it is the reason the rest of this article exists.

What does a long course of steroids actually cost me?

Enough that the guideline caps it. The cumulative dose of intravenous glucocorticoids should not exceed eight grams, and a ceiling written into a treatment recommendation is a statement about exposure rather than about any one infusion.

What that means in a clinic room is that these are monitored drugs, not background ones. Blood sugar, blood pressure, weight, sleep, mood and bone health are the things a treating team keeps an eye on through a course, and they are checked because steroid exposure adds up rather than because any one of them is expected. I am not going to attach a number to any of them here. The honest position is that they vary enormously between patients, and quoting a rate I cannot properly source would be worse than saying so.

There is no version of this where a patient stays on steroids indefinitely and calls it control. That is the pressure behind the next section.

What can be used instead of steroids, or alongside them?

Several agents, and the first is already in the first-line regimen. Mycophenolate is combined with intravenous methylprednisolone so that the steroid is not carrying the whole load. Below is what happens when that first line does not deliver.

If the response is poor and the disease is still moderate to severe and active, the guideline names six second-line options, after careful eye and blood work review: a second course of intravenous methylprednisolone, oral prednisolone combined with either ciclosporin or azathioprine, orbital radiotherapy combined with oral or intravenous steroids, teprotumumab, rituximab, and tocilizumab. Ciclosporin with oral steroid is described there as a valid second-line treatment.

That combination is the one I have studied most closely. With colleagues in Leeds I reviewed fourteen years of a tertiary oculoplastic service, looking at disease activity control and steroid reduction with ciclosporin in thyroid eye disease, work presented to the British Oculoplastic Surgery Society in 2026 and listed with my other research. What draws me to that question is the reason for this whole section: the goal is not simply to suppress the disease, it is to suppress it while getting the person off high-dose steroid.

One caveat belongs here and it is not a comfortable one. That list is international guidance, written where it was written. Whether any particular agent on it is genuinely available to you, in the country you are being treated in and under the funding arrangements you have, is a separate question with a separate answer, and it is not one I am going to settle with a sentence on a website. It is worth asking out loud at the appointment rather than discovering the answer six months into a plan built around a drug nobody can actually obtain.

What happens if my sight is actually threatened?

The plan changes completely and the timescale becomes days. Sight-threatening disease means optic nerve involvement, corneal breakdown, or both, and it is treated with several high single doses of intravenous methylprednisolone a week rather than the weekly schedule described above.

For optic nerve involvement specifically, the guideline advises immediate treatment with half a gram to one gram of methylprednisolone daily for three consecutive days, or preferably on alternate days, with urgent orbital decompression if the response is absent or poor within one to two weeks. Corneal breakdown is addressed surgically straight away, and the road to it is worth understanding before you are on it, which is why I have written separately about the eyes that will not close properly.

Meanwhile, the things that change your own odds are unglamorous and real. Risk factors include smoking, thyroid dysfunction, a high level of TSH receptor antibodies, radioactive iodine treatment and high cholesterol. Every patient with thyroid eye disease should be urged to stop smoking, because smokers have more severe disease and respond less well to treatment. In mild active disease, controlling those risk factors along with local treatment, and a six-month course of selenium in selenium-deficient areas, is usually enough on its own.

If you take one thing from this, take the question to ask at your next appointment: is my disease active, and what is my score. It is a better question than how my eyes look, which has a longer and far more ordinary list of causes, set out in what actually makes eyes look tired. The rest of what happens inside the socket sits together under thyroid eye disease and the orbit. Appearance can be addressed later, and calmly. Activity cannot wait for you to get used to it.